🟢 Veraxa Biotech is trading 6.4% up today on positive BiTAC pipeline updates and German regulatory feedback

Veraxa Biotech is trading 6.4% up today at $2.25, reflecting investor enthusiasm for recent progress on its BiTAC cancer therapy platform.

• The company highlighted first-half 2026 pipeline advances and growing partnering interest for its proprietary technology.
• Management disclosed supportive German regulatory feedback on its lead BiTAC-TCE program, helping de-risk development and improve visibility on future clinical plans.